Patents by Inventor Eszter Nagy

Eszter Nagy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12274742
    Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.
    Type: Grant
    Filed: November 22, 2022
    Date of Patent: April 15, 2025
    Inventors: Eszter Nagy, Gábor Nagy, Valéria Szijárto, Zóltan Magyarics, Irina Mirkina, Luis Gauchalla, Adriana Badarau, Gerhild Zauner, Jolanta Lukasiewicz
  • Patent number: 12103962
    Abstract: The invention refers to an isolated antibody that specifically binds to O25b antigen of E. coli strains comprising at least an antibody heavy chain variable region (VH), which comprises any of the CDR1 to CDR3 sequences as listed in FIG. 1, and optionally further comprising an antibody light chain variable region (VL), which comprises any of the CDR4 to CDR6 sequences as listed in FIG. 1, or functionally active CDR variants of any of the forgoing CDR 1-6 sequences.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: October 1, 2024
    Assignee: X4 PHARMACEUTICALS (AUSTRIA) GMBH
    Inventors: Eszter Nagy, Gábor Nagy, Valéria Szijárto, Luis Guachalla, Maximiliano Vasquez
  • Patent number: 11529405
    Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.
    Type: Grant
    Filed: February 4, 2021
    Date of Patent: December 20, 2022
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Eszter Nagy, Gäbor Nagy, Valéria Szijárto, Zóltan Magyarics, Irina Mirkina, Luis Gauchalla, Adriana Badarau, Gerhild Zauner, Jolanta Lukasiewicz
  • Patent number: 11466074
    Abstract: The invention provides for an isolated antibody that specifically recognizes a galactan-III epitope of the lipopolysaccharide (LPS) O-antigen structure of Klebsiella pneumoniae, which epitope is incorporated in galactan-III repeating units, wherein the galactan-III repeating unit is a branched galactose homopolymer of Formula (I). The invention further provides for a pharmaceutical or diagnostic preparation comprising said antibody, and a method of producing said antibody.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: October 11, 2022
    Assignee: X4 PHARMACEUTICALS (AUSTRIA) GMBH
    Inventors: Valeria Szijarto, Gábor Nagy, Luis Guachalla, Zehra Visram, Eszter Nagy, Jolanta Katarzyna Lukasiewicz
  • Patent number: 11433080
    Abstract: A method of treating a subject in need of anti-coronavirus treatment by providing a prophylactic or therapeutic treatment which includes an antiviral effective amount of an Azelastine compound, where the antiviral effective amount is 0.1-500 ?g per dose. An Azelastine compound can also be used as an antiviral substance in a medicinal product for treating a biological surface to prevent coronavirus infection and/or coronavirus spread, or as a viral disinfectant.
    Type: Grant
    Filed: December 27, 2021
    Date of Patent: September 6, 2022
    Assignee: CEBINA GMBH
    Inventors: Eszter Nagy, Gabor Nagy, Valeria Szijarto, Robert Konrat
  • Patent number: 11273163
    Abstract: A method of treating a subject in need of anti-Coronavirus treatment comprising prophylactic or therapeutic treatment, with an antiviral effective amount of an Azelastine compound, wherein the antiviral effective amount is 0.1-500 ?g per dose; use of an Azelastine compound as an antiviral substance in a medicinal product for treating a biological surface to prevent from Coronavirus infection and/or Coronavirus spread, and use of an Azelastine compound as viral disinfectant.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: March 15, 2022
    Assignee: CEBINA GMBH
    Inventors: Eszter Nagy, Gabor Nagy, Valeria Szijarto, Robert Konrat
  • Patent number: 10940191
    Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: March 9, 2021
    Assignee: X4 PHARMACEUTICALS (AUSTRIA) GMBH
    Inventors: Eszter Nagy, Gábor Nagy, Valéria Szijárto, Zoltán Magyarics, Irina Mirkina, Luis Guachalla, Adriana Badarau, Gerhild Zauner, Jolanta Lukasiewicz
  • Patent number: 10759848
    Abstract: A cross-neutralizing monoclonal antibody that specifically recognizes a cross-reactive epitope of the lipopolysaccharide (LPS) antigen structure of Klebsiella pneumoniae, which is an O3b epitope, cross-reacting with an O3a epitope and an O3 epitope, wherein the antibody is characterized by specific CDR sequences or VH and VL sequences.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: September 1, 2020
    Assignees: ARSANIS Biosciences GmbH, Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.
    Inventors: Valeria Szijárto, Gábor Nagy, Luis Guachalla, Katharina Ramoni, Adriana Badarau, Eszter Nagy, Tim Rollenske, Hedda Wardemann, Irina Mirkina
  • Patent number: 10206992
    Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: February 19, 2019
    Assignee: ARSANIS BIOSCIENCES GMBH
    Inventors: Eszter Nagy, Gábor Nagy, Valéria Szijárto, Zoltán Magyarics, Irina Mirkina, Luis Guachalla, Adriana Badarau, Gerhild Zauner, Jolanta Lukasiewicz
  • Patent number: 9914767
    Abstract: The subject relates to a cross-neutralizing antibody comprising at least one polyspecific binding site that binds to alpha-toxin (Hla) and at least one of the bi-component toxins of Staphylococcus aureus, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated conformational epitope recognized by a specific cross-neutralizing antibody.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: March 13, 2018
    Assignee: ARSANIS BIOSCIENCES GMBH
    Inventors: Eszter Nagy, Adriana Badarau, Harald Rouha, Lukas Stulik, Gábor Nagy, Irina Mirkina, Zoltán Magyarics, Zehra Visram, Michaela Jaegerhofer, Manuel Zerbs, Ivana Dolezilkova, Astrid Teubenbacher, Michael Benjamin Battles, Bianka Dominique Prinz
  • Patent number: 9849169
    Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: December 26, 2017
    Assignee: ARSANIS Biosciences GmbH
    Inventors: Eszter Nagy, Gábor Nagy, Valéria Szijárto, Zoltán Magyarics, Irina Mirkina, Luis Guachalla, Adriana Badarau, Gerhild Zauner, Jolanta Lukasiewicz
  • Patent number: 9730991
    Abstract: A live attenuated Shigella vaccine, which is based on a rough Shigella strain lacking LPS O-antigen which is non-invasive through a mutation of the invasion plasmid, specifically for use in the immunoprophylaxis of a subject to prevent infectious diseases, preferably enteral disease, and a Shigella strain, which is a S. flexneri 2a strain with a deletion of the rfb F, ipa B and/or ipa C genes, as well as a recombinant plasmid vector based on a mutated Shigella invasion plasmid comprising a nucleotide sequence encoding at least one heterologous antigen, wherein the plasmid is mutated in at least one of the ipa B and/or ipa C genes.
    Type: Grant
    Filed: September 5, 2013
    Date of Patent: August 15, 2017
    Assignee: EVELIQURE BIOTECHNOLOGIES GMBH
    Inventors: Gábor Nagy, Tamás Henics, Valeria Szijárto, Eszter Nagy
  • Publication number: 20160108106
    Abstract: The subject relates to an isolated Staphylococcus aureus leukocidin antigen comprising a LukGH complex, an antibody specifically binding to the Luk GH complex, and the human CD11b/CD18 complex for use in a method of determining the binding or toxicity of the Staphylococcus aureus Luk GH bi-component cytolysin.
    Type: Application
    Filed: May 16, 2014
    Publication date: April 21, 2016
    Inventors: Eszter Nagy, Adriana Badarau, Harald Rouha, Zoltán Magyarics, Sophia Zettl, Michael Benjamin Battles
  • Publication number: 20150246107
    Abstract: A live attenuated Shigella vaccine, which is based on a rough Shigella strain lacking LPS O-antigen which is non-invasive through a mutation of the invasion plasmid, specifically for use in the immunoprophylaxis of a subject to prevent infectious diseases, preferably enteral disease, and a Shigella strain, which is a S. flexneri 2a strain with a deletion of the rfb F, ipa B and/or ipa C genes, as well as a recombinant plasmid vector based on a mutated Shigella invasion plasmid comprising a nucleotide sequence encoding at least one heterologous antigen, wherein the plasmid is mutated in at least one of the ipa B and/or ipa C genes.
    Type: Application
    Filed: September 5, 2013
    Publication date: September 3, 2015
    Applicant: EVELIQURE BIOTECHNOLOGIES GMBH
    Inventors: Gábor Nagy, Tamás Henics, Valeria Szijárto, Eszter Nagy
  • Publication number: 20150086539
    Abstract: The subject relates to a cross-neutralizing antibody comprising at least one polyspecific binding site that binds to alpha-toxin (Hla) and at least one of the bi-component toxins of Staphylococcus aureus, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated conformational epitope recognized by a specific cross-neutralizing antibody.
    Type: Application
    Filed: April 17, 2013
    Publication date: March 26, 2015
    Inventors: Eszter Nagy, Adriana Badarau, Harald Rouha, Lukas Stulik, Gábor Nagy, Irina Mirkina, Zoltán Magyarics, Zehra Visram, Michaela Jaegerhofer, Manuel Zerbs, Ivana Dolezilkova, Astrid Teubenbacher, Michael Benjamin Battles, Bianka Dominique Prinz
  • Patent number: 8952135
    Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. agalactiae, and methods for isolating such antigens and specific uses thereof.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: February 10, 2015
    Assignee: Valneva Austria GmbH
    Inventors: Andreas Meinke, Eszter Nagy, Markus Hanner, Markus Horky, Sabine Kallenda, Sonja Prustomersky
  • Patent number: 8900564
    Abstract: The invention relates to a vaccine which comprises at least one antigen and a peptide comprising a sequence R1—XZXZNXZX—R2, whereby N is a whole number between 3 and 7, preferably 5, X is a positively charged natural and/or non-natural amino acid residue, Z is an amino acid residue selected from the group consisting of L, V, I, F and/or W, and R1 and R2 are selected independently one from the other from the group consisting of —H, —NH2, —COCH3, —COH, a peptide with up to 20 amino acid residues or a peptide reactive group or a peptide linker with or without a peptide; X—R2 may also be an amide, ester or thioester of the C-terminal amino acid residue, as well as the use of said peptide for enhancing a patient's adaptive immune response to an antigen.
    Type: Grant
    Filed: May 21, 2008
    Date of Patent: December 2, 2014
    Assignee: Valneva Austria GmbH
    Inventors: Jörg Fritz, Frank Mattner, Wolfgang Zauner, Eszter Nagy, Michael Buschle
  • Patent number: 8795690
    Abstract: The invention relates to a composition comprising at least two protective proteins against Streptococcus agalactiae (S. agalactiae) or functionally active variant thereof; a protective peptide against S. agalactiae; one or more nucleic acid(s) encoding the at least two proteins and/or the protective peptide; a method of producing the composition; a pharmaceutical composition, especially a vaccine, comprising the composition and/or at least one protective peptide; methods for producing antibodies; a mixture of antibodies against the at least two proteins of the composition; the use of the composition and/or at least one protective peptide and/or one or more nucleic acid(s) for the manufacture of a medicament for the immunization or treatment of a subject; methods of diagnosing a S.
    Type: Grant
    Filed: November 26, 2012
    Date of Patent: August 5, 2014
    Assignee: Valneva Austria GmbH
    Inventors: Beatrice Tschanun, Eszter Nagy, Andreas Meinke, Alexander Von Gabain, Barbara Maierhofer, Ulrike Stierschneider, Manfred Berger, Christina Neubauer, Katherine Cohen
  • Patent number: 8715688
    Abstract: Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to auto-immunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps: providing an antibody preparation, providing at least one expression library, identifying antigens which bind, screening the identified antigens, identifying the hyperimmune serum-reactive antigen portion of said identified antigens and which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: May 6, 2014
    Assignee: Valneva Austria GmbH
    Inventors: Andreas Meinke, Eszter Nagy, Uwe Von Ahsen, Christoph Klade, Tamas Henics, Wolfgang Zauner, Duc Bui Minh, Oresta Vytvytska, Hildegard Etz, Agnieszka Dryla, Thomas Weichhart, Martin Hafner, Brigitte Tempelmaier, Claire M. Fraser, Steven Gill
  • Patent number: 8637052
    Abstract: The present invention relates to an isolated nucleic acid molecule encoding an antigen, a vector comprising such nucleic acid molecule and a host cell comprising such vector. Furthermore, the invention provides antigens from Klebsiella species, fragments and variants thereof, a process for producing such antigens, and a process for producing cells expressing such antigens. Moreover, the present invention provides antibodies binding to such antigen, hybridoma cells producing such antibodies, methods for producing such antibodies, a pharmaceutical composition comprising such nucleic acid molecule, antigen, vector or antibody, the use of such nucleic acid molecule, antigen, vector or antibody for the preparation of a pharmaceutical composition, methods for identifying an antagonist capable of binding such antigen or of inhibiting the interaction activity of such antigen, methods for diagnosis or for treatment or prevention of an infection.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: January 28, 2014
    Assignee: Valneva Austria GmbH
    Inventors: Sharmila Bakshi, Thomas Cipps, Markus Hanner, Jutta Pikalo, Christina Satke, Eszter Nagy, Urban Lundberg, Dagmar Zierer, Andreas Meinke, Birgit Noiges, Ulrike Stierschneider, Alexander Von Gabain